Regulators are reviewing what could become a multi-billion-dollar drug.
Mink now holds a camp-sized (100 km2) land package within the highly prospective Montcalm Gabbro Complex (MGC), adjoining the ...
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T ...